Literature DB >> 10991849

Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla(TEM) genes.

V Leflon-Guibout1, V Speldooren, B Heym, M Nicolas-Chanoine.   

Abstract

Amoxicillin-clavulanate resistance (MIC >16 microg/ml) and the corresponding molecular mechanisms were prospectively studied in Escherichia coli over a 3-year period (1996 to 1998) in 14 French hospitals. The overall frequency of resistant E. coli isolates remained stable at about 5% over this period. The highest frequency of resistant isolates (10 to 15%) was observed, independently of the year, among E. coli isolated from lower respiratory tract samples, and the isolation rate of resistant strains was significantly higher in surgical wards than in medical wards in 1998 (7.8 versus 2.8%). The two most frequent mechanisms of resistance for the 3 years were the hyperproduction of the chromosomal class C beta-lactamase (48, 38.4, and 39.7%) and the production of inhibitor-resistant TEM (IRT) enzymes (30.4, 37.2, and 41.2%). By using the single-strand conformational polymorphism-PCR technique and sequencing methods, we determined that 59 IRT enzymes corresponded to previously described IRT enzymes whereas 8 were new. Three of these new enzymes derived from TEM-1 by only one amino acid substitution (Ser130Gly, Arg244Gly, and Asn276Asp), whereas three others derived by two amino acid substitutions (Met69Leu and Arg244Ser, Met69Leu and Ile127Val, and Met69Val and Arg275Gln). The two remaining new IRTs showed three amino acid substitutions (Met69Val, Trp165Arg, and Asn276Asp and Met69Ile, Trp165Cys, and Arg275Gln). New genetic features were also found in bla(TEM) genes, namely, bla(TEM-1B) with either the promoters Pa and Pb, P4, or a promoter displaying a C-->G transversion at position 3 of the -35 consensus sequence and new bla(TEM) genes, notably one encoding TEM-1 but possessing the silent mutations originally described in bla(TEM-2) and then in some bla(TEM)-encoding IRT enzymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991849      PMCID: PMC90140          DOI: 10.1128/AAC.44.10.2709-2714.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Statement 1996 CA-SFM Zone sizes and MIC breakpoints for non-fastidious organisms.

Authors: 
Journal:  Clin Microbiol Infect       Date:  1996-02       Impact factor: 8.067

2.  Molecular diversity and evolution of blaTEM genes encoding beta-lactamases resistant to clavulanic acid in clinical E. coli.

Authors:  M M Caniça; C Y Lu; R Krishnamoorthy; G C Paul
Journal:  J Mol Evol       Date:  1997-01       Impact factor: 2.395

3.  Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).

Authors:  I Simpson; J Durodie; S Knott; B Shea; J Wilson; K Machka
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains.

Authors:  D Lepelletier; N Caroff; A Reynaud; H Richet
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

5.  Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.

Authors:  P Stapleton; P J Wu; A King; K Shannon; G French; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Two improved promoter sequences for the beta-lactamase expression arising from a single base-pair substitution.

Authors:  S T Chen; R C Clowes
Journal:  Nucleic Acids Res       Date:  1984-04-11       Impact factor: 16.971

7.  Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.

Authors:  P A Bradford; C Urban; N Mariano; S J Projan; J J Rahal; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

8.  Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 beta-lactamase (LAT-2).

Authors:  M Gazouli; L S Tzouvelekis; E Prinarakis; V Miriagou; E Tzelepi
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

9.  Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The Vigil'Roc Study Group.

Authors:  F W Goldstein; Y Péan; J Gertner
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

10.  Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals. The 1990 Dutch Surveillance Study.

Authors:  R J Buirma; A M Horrevorts; J H Wagenvoort
Journal:  Scand J Infect Dis Suppl       Date:  1991
View more
  34 in total

1.  Updated sequence information and proposed nomenclature for bla(TEM) genes and their promoters.

Authors:  V Leflon-Guibout; B Heym; M Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Inhibitor-resistant TEM-33 beta-lactamase in a Shigella sonnei isolate.

Authors:  D Sirot; C Chanal; R Bonnet; C De Champs; L Bret
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

Review 3.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

4.  TEM-71, a novel plasmid-encoded, extended-spectrum beta-lactamase produced by a clinical isolate of Klebsiella pneumoniae.

Authors:  J Kamile Rasheed; Gregory J Anderson; Anne Marie Queenan; James W Biddle; Antonio Oliver; George A Jacoby; Karen Bush; Fred C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

5.  Resistance to beta-lactamase inhibitor protein does not parallel resistance to clavulanic acid in TEM beta-lactamase mutants.

Authors:  William A Schroeder; Troy R Locke; Susan E Jensen
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  TEM-103/IRT-28 beta-lactamase, a new TEM variant produced by Escherichia coli BM4511.

Authors:  Rodrigo Alonso; Guy Gerbaud; Marc Galimand; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

7.  Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period.

Authors:  Elisenda Miró; Ferran Navarro; Beatriz Mirelis; Montserrat Sabaté; Alba Rivera; Pere Coll; Guillem Prats
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  Promoters P3, Pa/Pb, P4, and P5 upstream from bla(TEM) genes and their relationship to beta-lactam resistance.

Authors:  Marie Frédérique Lartigue; Véronique Leflon-Guibout; Laurent Poirel; Patrice Nordmann; Marie-Hélène Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

9.  Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum beta-lactamase CTX-M-9.

Authors:  C Aumeran; C Chanal; R Labia; D Sirot; J Sirot; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Beta-lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals.

Authors:  Laura Briñas; Myriam Zarazaga; Yolanda Sáenz; Fernanda Ruiz-Larrea; Carmen Torres
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.